Market Access for Digital Health Assets: Creating Frameworks for Digital Health Technologies

Digital health technologies are revolutionizing the healthcare landscape through innovations such as wearable devices, telehealth platforms, AI-driven diagnostics, and digital therapeutics. Digital health technologies have the potential to enhance patient care, improve outcomes, and reduce costs. However, the journey from concept to widespread adoption of digital health technologies is fraught with challenges. Creating effective frameworks for market access is key to overcoming these hurdles. This involves demonstrating how these technologies benefit end users, facilitating adoption, and ensuring that the right treatment reaches the right patient at the right time and at the right price. By establishing these frameworks, it is possible to seamlessly integrate digital health assets into mainstream healthcare, ultimately transforming the industry.[1,2]

Billions of dollars are invested worldwide in medical product development, including digital health assets, increasing the pressure to maximize the revenues of these investments. A market access decision clearly assumes a thorough understanding of decision-making in various health systems. For digital health technologies, market access involves navigating regulatory requirements, securing reimbursement, and achieving widespread adoption among healthcare providers and patients.[3,4]

Regulatory bodies like the FDA in the United States and the EMA in Europe play a pivotal role in ensuring the safety, efficacy, and reliability of digital health products. The FDA’s Digital Health Innovation Action Plan, for instance, provides a clear roadmap for developers, emphasizing the need for robust clinical evidence and post-market surveillance. Understanding and adhering to these regulations not only accelerates market entry but also builds trust among healthcare providers and patients.[5]

Reimbursement models are pivotal for ensuring the financial viability of digital health technologies. They dictate how these services and products are paid for: through insurance, government programs, or out-of-pocket payments by patients. In many countries, government bodies and regulatory agencies are key stakeholders, influencing healthcare policy and setting pricing and reimbursement guidelines.[6] For instance, they may administer financing assistance programs (like the Medical Devices program, which provides regulatory and financial support to companies, or the breakthrough devices program, aimed at facilitating access to medical devices treating life-threatening or disabling conditions). Insurance companies also play a significant role, albeit with limitations that can create financial barriers for uninsured patients.[7]

Despite these challenges, establishing clear and sustainable reimbursement pathways is essential for driving the widespread adoption of digital health technologies. Integrating these services into existing insurance plans can serve as a powerful incentive for healthcare providers to embrace these innovations and enhance patient care.[7]

Engaging key stakeholders – including healthcare providers, patients, payers, and policymakers is vital for the successful market entry of digital health technologies. Stakeholder engagement helps to address concerns, gather valuable feedback, and build a coalition of supporters. For instance, involving clinicians in the development process can ensure that the technology meets their needs and integrates seamlessly into their workflows. Similarly, patient engagement can enhance the usability and acceptance of digital health tools, ensuring they are user-friendly and address real patient needs.[8]

A 2021 study underscores the importance of this approach, revealing that all stakeholder groups -including venture capitalists, digital health companies, payers, and providers – were of the opinion that the engagement of frontline providers and patients was a crucial driver for the widespread uptake of patient-facing digital too. This highlights the importance of collaborative efforts and the significant role of engagement in overcoming adoption barriers, ultimately fostering a supportive environment for digital health innovations.[9]

The future of market access for digital health assets lies in embracing innovation and maintaining flexibility in regulatory and reimbursement frameworks. As digital health technologies continue to evolve, frameworks must adapt to accommodate new advancements. This could involve developing agile regulatory processes that expedite the approval of low-risk digital health products or creating innovative reimbursement models that reflect the unique value propositions of digital health solutions. Additionally, ensuring robust data privacy and security measures will be essential to safeguard patient information and build user confidence, facilitating the broader adoption of these technologies. By addressing both regulatory agility and data protection, the full potential of digital health assets can be potentially unlocked, thereby taking a step to further improve healthcare outcomes.[10]

In conclusion, market access for digital health assets is a multi-faceted journey that requires comprehensive frameworks addressing regulatory compliance, reimbursement models, stakeholder engagement, and future-proofing through innovation and flexibility. By developing these frameworks, we can ensure that digital health technologies reach their full potential, transforming the healthcare landscape and delivering better health outcomes for all. Continuous collaboration among stakeholders and a commitment to adapting to new advancements will be key to successfully navigating this evolving field.

Become A Certified HEOR Professional – Enrol yourself?here!

References

1. Fraser AG, Nelissen RG, Kj?rsgaard-Andersen P, Szymański P, Melvin T, Piscoi P. Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE–MD (Coordinating Research and Evidence for Medical Devices). EFORT open reviews. 2021 Oct 19;6(10):839-49.
2. Farah L, Borget I, Martelli N. International Market Access Strategies for Artificial Intelligence–Based Medical Devices: Can We Standardize the Process to Faster Patient Access?. Mayo Clinic Proceedings: Digital Health. 2023 Sep 1;1(3):406-12.
3. Dorsey ER, De Roulet J, Thompson JP, Reminick JI, Thai A, W et al. Funding of US biomedical research, 2003-2008. Jama. 2010 Jan 13;303(2):137-43.
4. Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Applied health economics and health policy. 2011 Sep;9:331-47.
5. FDA. Digital Health Innovation Action Plan. Retrieved from https://www.fda.gov/media/106331/download
6. Chinyio E, Olomolaiye P, editors. Construction stakeholder management. John Wiley & Sons; 2009 Oct 22.
7. Woo JH, Kim EC, Kim SM. The current status of breakthrough devices designation in the United States and innovative medical devices designation in Korea for digital health software. Expert Review of Medical Devices. 2022 Mar 4;19(3):213-28.
8. Vat LE, Finlay T, Robinson P, Barbareschi G, Boudes M, et al. Evaluation of patient engagement in medicine development: A multi‐stakeholder framework with metrics. Health Expectations. 2021 Apr;24(2):491-506.
9. Lyles CR, Adler-Milstein J, Thao C, Lisker S, Nouri S, Sarkar U. Alignment of key stakeholders’ priorities for patient-facing tools in digital health: mixed methods study. Journal of Medical Internet Research. 2021 Aug 26;23(8):e24890.
10. Rockwern B, Johnson D, Snyder Sulmasy L, Medical Informatics Committee and Ethics, Professionalism and Human Rights Committee of the American College of Physicians. Health information privacy, protection, and use in the expanding digital health ecosystem: a position paper of the American College of Physicians. Annals of Internal Medicine. 2021 Jul;174(7):994-8.